OPEN END TURBO PUT WARRANT - GILEAD SCIENCES | Delayed Deutsche Boerse AG 12:03:46 31/05/2024 BST | ||
| 5.49 EUR | +2.43% |
|
| Current month | +0.56% | ||
| 1 month | +0.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 5.49 | +2.43% |
| 30/05/24 | 5.36 | -1.83% |
| 29/05/24 | 5.46 | +1.68% |
| 28/05/24 | 5.37 | +3.07% |
| 27/05/24 | 5.21 | -0.76% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 12:03 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UK9F4V |
| ISIN | DE000UK9F4V5 |
| Date issued | 16/11/2022 |
| Strike | 121.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.54 € |
|---|---|
| Lowest since issue | 3.2 € |
| Spread | 0.03 € |
| Spread % | 0.55% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.08
USD
Average target price
82.7
USD
Spread / Average Target
+29.05%
- Stock Market
- Certificates
- Certificat
